Radiopharm Theranostics Ltd (RADX) EBITDA (2023 - 2026)

Radiopharm Theranostics (RADX) has reported EBITDA for 4 consecutive years, with -$706093.8 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 98.15% year-over-year to -$706093.8 in Q2 2026; TTM through Jun 2026 was -$73.6 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$385651.8, up 98.99% from the prior year.
• EBITDA was -$706093.8 for Q2 2026 at Radiopharm Theranostics, up from -$38.2 million in the prior quarter.
• Over five years, EBITDA peaked at -$258373.8 in Q2 2024 and troughed at -$38.2 million in Q2 2025.
• A 4-year average of -$18.4 million and a median of -$17.6 million in 2026 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 99.25% in 2024 and sank 14672.85% in 2025, its largest moves.
• Over 4 years, EBITDA stood at -$34.5 million in 2023, then surged by 99.25% to -$258373.8 in 2024, then slumped by 14672.85% to -$38.2 million in 2025, then soared by 98.15% to -$706093.8 in 2026.
• The last three EBITDA figures came in at -$706093.8 (Q2 2026), -$38.2 million (Q2 2025), and -$258373.8 (Q2 2024), per Business Quant data.